JP2025160458A5 - - Google Patents

Info

Publication number
JP2025160458A5
JP2025160458A5 JP2025130097A JP2025130097A JP2025160458A5 JP 2025160458 A5 JP2025160458 A5 JP 2025160458A5 JP 2025130097 A JP2025130097 A JP 2025130097A JP 2025130097 A JP2025130097 A JP 2025130097A JP 2025160458 A5 JP2025160458 A5 JP 2025160458A5
Authority
JP
Japan
Prior art keywords
acid sequence
seq
set forth
amino acid
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025130097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025160458A (ja
Filing date
Publication date
Priority claimed from JP2022096901A external-priority patent/JP7286845B2/ja
Application filed filed Critical
Publication of JP2025160458A publication Critical patent/JP2025160458A/ja
Publication of JP2025160458A5 publication Critical patent/JP2025160458A5/ja
Pending legal-status Critical Current

Links

JP2025130097A 2015-12-15 2025-08-04 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 Pending JP2025160458A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562267735P 2015-12-15 2015-12-15
US62/267,735 2015-12-15
US201662309169P 2016-03-16 2016-03-16
US62/309,169 2016-03-16
US201662359036P 2016-07-06 2016-07-06
US62/359,036 2016-07-06
JP2022096901A JP7286845B2 (ja) 2015-12-15 2022-06-15 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用
JP2023085801A JP7790837B2 (ja) 2015-12-15 2023-05-24 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023085801A Division JP7790837B2 (ja) 2015-12-15 2023-05-24 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用

Publications (2)

Publication Number Publication Date
JP2025160458A JP2025160458A (ja) 2025-10-22
JP2025160458A5 true JP2025160458A5 (https=) 2025-12-22

Family

ID=59057509

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018530560A Active JP6858779B2 (ja) 2015-12-15 2016-12-14 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用
JP2021049294A Pending JP2021100957A (ja) 2015-12-15 2021-03-23 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用
JP2022096901A Active JP7286845B2 (ja) 2015-12-15 2022-06-15 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用
JP2023085801A Active JP7790837B2 (ja) 2015-12-15 2023-05-24 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用
JP2025130097A Pending JP2025160458A (ja) 2015-12-15 2025-08-04 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2018530560A Active JP6858779B2 (ja) 2015-12-15 2016-12-14 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用
JP2021049294A Pending JP2021100957A (ja) 2015-12-15 2021-03-23 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用
JP2022096901A Active JP7286845B2 (ja) 2015-12-15 2022-06-15 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用
JP2023085801A Active JP7790837B2 (ja) 2015-12-15 2023-05-24 キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用

Country Status (26)

Country Link
US (3) US10618960B2 (https=)
EP (2) EP4374926A3 (https=)
JP (5) JP6858779B2 (https=)
KR (2) KR102830926B1 (https=)
CN (2) CN108430499B (https=)
AU (3) AU2016370648B2 (https=)
BR (1) BR112018012113A2 (https=)
CA (1) CA3006984C (https=)
DK (1) DK3389699T5 (https=)
ES (1) ES2979210T3 (https=)
FI (1) FI3389699T3 (https=)
HR (1) HRP20240719T1 (https=)
HU (1) HUE066907T2 (https=)
IL (3) IL296354B2 (https=)
LT (1) LT3389699T (https=)
MX (3) MX2018006925A (https=)
MY (1) MY186974A (https=)
PL (1) PL3389699T3 (https=)
PT (1) PT3389699T (https=)
RS (1) RS65703B1 (https=)
SG (1) SG11201804969PA (https=)
SI (1) SI3389699T1 (https=)
SM (1) SMT202400211T1 (https=)
TW (1) TWI739781B (https=)
WO (1) WO2017106372A1 (https=)
ZA (1) ZA201804077B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
WO2018053506A1 (en) * 2016-09-19 2018-03-22 Oncoimmune, Inc. Cd80 and cd86 binding protein compositions and uses thereof
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
JP2021502100A (ja) * 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
JP7490923B2 (ja) * 2018-02-02 2024-05-28 オンコシーフォー、インク． 免疫療法効果が向上し副作用が軽減した変異抗ｃｔｌａ－４抗体
AU2019216228A1 (en) * 2018-02-02 2020-08-13 Children's Research Institute, Children's National Medical Center Methods of selecting and designing safer and more effective anti-CTLA-4 antibodies for cancer therapy
CN115991787A (zh) 2018-06-05 2023-04-21 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
AU2019413366B2 (en) * 2018-12-27 2025-06-05 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
US12559565B2 (en) 2020-04-13 2026-02-24 Biosion Inc. Antibodies binding CTLA4 and uses thereof
EP4142792A4 (en) 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022169269A1 (ko) * 2021-02-03 2022-08-11 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
AU2022253351A1 (en) 2021-04-09 2023-10-12 Boehringer Ingelheim International Gmbh New scaffold for bifunctional molecules with improved properties
JP7345889B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
WO2023057994A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
EP4392156A4 (en) * 2021-10-08 2025-06-25 Kashiv Biosciences, LLC Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
EP4431528A1 (en) * 2021-10-29 2024-09-18 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
CN118176021A (zh) 2021-10-29 2024-06-11 昂科医药 抗ctla-4抗体给药方案
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
JP2025531229A (ja) 2022-09-16 2025-09-19 オンコシーフォー、インク． 腺様嚢胞がんを処置するための抗ｃｔｌａ－４抗体の使用
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy
AU2024254671A1 (en) 2023-03-30 2025-10-02 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
CN121358499A (zh) 2023-03-30 2026-01-16 Ose免疫疗法 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途
AU2024262223A1 (en) 2023-04-28 2025-11-27 Acroimmune Biopharma Co., Ltd. Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof
EP4724498A2 (en) * 2023-06-09 2026-04-15 The Regents of the University of California Methods for identifying and correcting tumor humoral immune dysfunction
WO2025133186A1 (en) 2023-12-22 2025-06-26 OncoC4, Inc. Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
WO2025234450A1 (ja) * 2024-05-08 2025-11-13 学校法人帝京平成大学 改変がん細胞及びそれを含むがんワクチン組成物
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026041780A2 (en) 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment
WO2026057739A1 (en) 2024-09-12 2026-03-19 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1210424B1 (en) 1999-08-23 2007-02-07 Dana-Farber Cancer Institute, Inc. Novel b7-4 molecules and uses therefor
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
EP1261376A1 (en) * 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20090252741A1 (en) * 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
US20080152655A1 (en) * 2004-09-08 2008-06-26 The Ohio State University Research Foundation Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies
JP4938673B2 (ja) 2004-10-15 2012-05-23 ベリサイン・インコーポレイテッド ワンタイムパスワード
DK1853631T3 (en) * 2005-01-24 2016-03-29 Univ Texas Fc-FUSION CONSTRUCTIONS BINDING TO PHOSPHATIDYLSERINE AND THERAPEUTIC APPLICATION THEREOF
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
CN101628940B (zh) * 2008-07-15 2011-11-23 中国科学院生物物理研究所 一种单克隆抗体及其应用
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
EP2794878B1 (en) * 2011-12-22 2020-03-18 F.Hoffmann-La Roche Ag Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
WO2013142796A2 (en) * 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
CN104968364A (zh) * 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104292334B (zh) * 2014-04-25 2018-11-27 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
WO2018053506A1 (en) 2016-09-19 2018-03-22 Oncoimmune, Inc. Cd80 and cd86 binding protein compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2025160458A5 (https=)
JP2025111463A5 (https=)
RU2019128134A (ru) Антитело против gprc5d и молекула, содержащая антитело
JP2020534830A5 (https=)
GEP20074222B (en) Antibodies to cd40
RU2011116112A (ru) Биспецифические анти-egfr/анти-igf-1r антитела
WO2006071441A3 (en) Antibodies directed to gpnmb and uses thereof
EA200602276A1 (ru) Антитела против cd3 и способы их применения
JP2009518039A5 (https=)
CA2583910A1 (en) Angiopoietin-2 specific binding agents
NZ601342A (en) Antibodies that bind il-4 and/or il-13 and their uses
RU2019143101A (ru) Новое анти-с-мет антитело и его применение
JP2018505681A5 (https=)
JP2020533016A5 (https=)
JP2012519492A5 (https=)
JP2021520832A5 (https=)
JP2025038088A5 (https=)
JP2024001073A5 (https=)
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2020518243A5 (https=)
JP2022500455A5 (https=)
JPWO2019201959A5 (https=)
JPWO2021224913A5 (https=)
JP2021514369A5 (https=)
JPWO2023091614A5 (https=)